Valeant's Paulson Boost, Plus 2 Rival Drug Stocks Moving Big on Trial Data

Hedge fund manager John Paulson is taking a seat on the Valeant Pharmaceuticals board

Managing Editor
Jun 19, 2017 at 10:40 AM
facebook twitter linkedin

U.S. stocks are rising today, boosted by big-cap tech names. Among specific names on the move today are drug stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX), cancer treatment developer Clovis Oncology Inc (NASDAQ:CLVS), and drugmaker TESARO Inc (NASDAQ:TSRO). Here's a quick look at what's moving shares of VRX, CLVS, and TSRO.

Board Addition Boosts VRX Stock

Valeant Pharmaceuticals stock jumped 3% to trade at $13.07, after news broke that hedge fund manager John Paulson was elected to the company's board of directors. Paulson's own hedge fund is Valeant's largest shareholder.

VRX is down 10% year-to-date, and the stock is staring up at its 150-day moving average, which capped a mid-May rally attempt. However, with the shares up 57% from April's eight-year low of $8.31, options traders are favoring calls. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows VRX with a 50-day call/put volume ratio of 2.83, ranking in the 97th percentile of its annual range.

Upbeat Drug Data Sends CLVS Stock Soaring

Clovis Oncology stock is roaring today, up 40% to trade at $84.92, after its ovarian cancer drug Rubraca delivered positive results in a late-stage study. Clovis plans to submit the drug for a label expansion soon, which would allow the treatment to be used for longer periods in a wider range of patients. The boost today sends CLVS stock to an 18-month high of $91, with the stock bouncing strongly off its 80-day moving average.

Heading into today's announcement, options traders were bracing for big moves from CLVS. The equity's Schaeffer's Volatility Index (SVI) of 1.50 rates higher than 90% of all other readings from the past year, indicating that front-month options have priced in higher volatility expectations only 10% of the time during the past year.

TSRO Stock Stumbles After Rival Drug Study Succeeds

Tesaro stock is down 6% to trade at $135.22, after rival Clovis Oncology reported positive results for its cancer treatment drug. TSRO shares have been declining steadily from their Feb. 21 all-time high of $192.94, and today's drop has the stock on pace to close below its 200-day moving average for the first time since its big bullish gap in June 2016.

Analysts remain optimistic, however. Nine out of 16 brokerages covering TSRO stock rate it a "buy" or better, which leaves the door open for downgrades going forward.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners